Pluristem Therapeutics  logo
Pluristem Therapeutics PSTI
report update icon

Quarterly report 2026-Q4
added 09-10-2026

Pluristem Therapeutics Financial Statements 2026-2009 | PSTI

Annual Financial Statements Pluristem Therapeutics

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

- 6.53 M 5.4 M 4.72 M 33.2 M 28.1 M 167 M 69.1 M 130 M 103 M 118 M 167 M 181 M 168 M 147 M 107 M - -

Shares

9.74 M 6.34 M 5.24 M 4.58 M 32.2 M 28.1 M 18.2 M 12.3 M 10.6 M 8.74 M 7.95 M 7.03 M 6.35 M 5.55 M 4.4 M 3.12 M 20.9 M 13.7 M

Historical Prices

- 1.03 1.03 1.03 1.03 1.78 6.34 3.75 9.6 14.3 11.4 13 30.4 41.1 33.2 22.5 - -

Net Income

-23.8 M -22.6 M 21.3 M 28.9 M -41.2 M -49.9 M -29.2 M -35.3 M -26.1 M -27.8 M -23.2 M -24.7 M -26.9 M -21.2 M -14.8 M -10.8 M -2.82 M -

Revenue

1.02 M 1.34 M 326 K 287 K 234 K - 23 K 54 K 50 K - 2.85 M 379 K 379 K 679 K 716 K - - -

Cost of Revenue

563 K 682 K 4 K 9 K - - - 2 K 2 K - 100 K 13 K 11 K 20 K 21 K - - -

Gross Profit

453 K 654 K 322 K 278 K 234 K - 23 K 52 K 48 K - 2.75 M 366 K 368 K 659 K 716 K - - -

Operating Income

-24.9 M -22.2 M -22.2 M -27.2 M -41.6 M -50.6 M -29.5 M -35.5 M -33.7 M -28 M -23.3 M -25.3 M -27.8 M -22.2 M -15 M -11.1 M -2.82 M -

Interest Expense

476 K -206 K 1.68 M 843 K 887 K 78 K - -2 K -25 K - 23 K - - - - - - -

EBITDA

-24.4 M -21.9 M -21.9 M -26.9 M -40.5 M -49.3 M -27.9 M -33.6 M -31.7 M -25.8 M -21.2 M -23.2 M -25.9 M -21.2 M -14.6 M -10.8 M -2.62 M -

Operating Expenses

- - - - - - 29.5 M 35.6 M 33.8 M 28 M 26.1 M 25.6 M 28.2 M 22.9 M 15.7 M 11.1 M 2.82 M -

General and Administrative Expenses

10.3 M 9.98 M 10 M 11.8 M 2.13 M 5.16 M 7.92 M 9.16 M 11.2 M 6.93 M 6.49 M 6.46 M 8.68 M 5.65 M - - 3.14 M -

All numbers in USD currency

Quarterly Income Statement Pluristem Therapeutics

2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 10.1 M 9.26 M 9 M 9.26 M 9 M 7.89 M 6.56 M 5.55 M 5.46 M 5.41 M 5.22 M 5.19 M 5.17 M 41.2 M 39.9 M 33.2 M 32.6 M 32.5 M 32.3 M 32.1 M 32 M 32.1 M 29.6 M 25.7 M 25.5 M 25.7 M 25.5 M 15.9 M 15.4 M 15.9 M 15.4 M 11.6 M 11.4 M 11.4 M 110 M 105 M 97.3 M 105 M 97.3 M 81 M 80.7 M 81 M 80.7 M 79.4 M 78.7 M 79.4 M 78.7 M 70.1 M 69.1 M 70.1 M 69.1 M 61.5 M 59.3 M 61.5 M 59.3 M 57.5 M 47.8 M 57.5 M 44.3 M 43.7 M 43 M 42.4 M 42.4 M

Net Income

- -5.55 M -6.54 M -5.85 M -6.54 M -5.85 M - -6.15 M -2.96 M -5.88 M - -5.29 M -4.9 M -4.96 M - -7.62 M -8.12 M -6.12 M -14.2 M -9.86 M -10.9 M -11.4 M -22.4 M -14.3 M -12.6 M -8.49 M -12.6 M -8.49 M -6.37 M -7.14 M -6.37 M -7.14 M -8.68 M -8.79 M - -1.53 M -8.23 M -7.38 M -8.23 M -7.38 M -6.61 M -6.32 M -6.61 M -6.32 M -3.96 M -5.88 M -3.96 M -5.88 M -6.24 M -5.91 M -6.24 M -5.91 M -6.7 M -4.76 M -6.7 M -4.76 M -4.49 M -4 M -4.49 K -4 M -1.99 K -4.49 M -1.99 M -4.49 M

Revenue

- 167 K 198 K 316 K 198 K 316 K - 427 K 185 K 326 K - 71 K 105 K 54 K - 87 K 2 K 87 K 89 K 234 K - - - - - 23 K - - 23 K 54 K 23 K - 50 K 4 K - - 50 K - 50 K - - 2.85 M - - 2.75 M 95 K 2.75 M 95 K 95 K 95 K 95 K 95 K 95 K 95 K 95 K 95 K 195 K 195 K 195 195 K 231 154 K 231 K 154 K

Cost of Revenue

- 111 K 112 K 201 K 112 K 201 K - 291 K 74 K 126 K - - - - - - - - - - - - - - - 1 K - - 1 K 2 K 1 K - 2 K 2 K - - 2 K - 2 K - - 100 K - - 97 K 3 K 97 K 3 K 4 K 3 K 4 K 3 K 3 K 3 K 3 K 3 K 6 K 6 K 6 6 K 7 5 K - -

Gross Profit

- 56 K 86 K 115 K 86 K 115 K - 136 K 111 K 200 K - 71 K 105 K 54 K - - - - - - - - - - - 22 K - - 22 K 52 K 22 K - 48 K 4 K - - 48 K - 48 K - - 2.75 M - - 2.66 M 92 K 2.66 M 92 K 91 K 92 K 91 K 92 K 92 K 92 K 92 K 92 K 189 K 189 K 189 189 K 224 149 K - -

Operating Income

- -6.54 M -6.51 M -6.35 M -6.51 M -6.35 M - -5.4 M -4.96 M -5.2 M - -5.53 M -5.21 M -5.38 M - -7.1 M -6.68 M -6.92 M -13.6 M -10.5 M -10.8 M -11.4 M -22.2 M -14.2 M -13.1 M -8.74 M -13.1 M -8.74 M -6.37 M -7.2 M -6.37 M -7.2 M -8.33 M -8.97 M - -9.05 M -8.47 M -7.44 M -8.47 M -7.44 M -6.65 M -6.56 M -6.65 M -6.56 M -4.23 M -5.52 M -4.23 M -5.52 M -6.3 M -5.62 M -6.3 M -5.62 M -6.99 M -4.86 M -6.99 M -4.86 M -4.88 M -4.19 M -4.88 K -4.19 M -2.12 K -4.33 M -2.12 M -4.33 M

Interest Expense

- 593 K -143 K 439 K -143 K 439 K - -723 K 2.06 M -621 K - 362 K 435 K 493 K - - 212 K 194 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- -6.41 M -6.38 M -6.22 M -6.38 M -6.22 M - - -4.89 M -5.13 M - - - -5.31 M - - -6.68 M -6.82 M -13.4 M -10.5 M -10.8 M -11.1 M -21.6 M -14.2 M -13.1 M -8.39 M -12.4 M -8.39 M -6.37 M -6.73 M -5.52 M -6.73 M -8.33 M -8.47 M - -9.05 M -8.47 M -6.92 M -7.44 M -6.92 M -6.65 M -6 M -5.54 M -6 M -4.23 M -5.03 M -3.2 M -5.03 M -6.3 M -5.12 M -5.3 M -5.12 M -6.99 M -4.4 M -6.05 M -4.4 M -4.88 M -4.06 M -4.61 K -4.06 M -2.12 K -4.24 M -1.92 M -4.24 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 4.95 M - - - 4.38 M 4.07 M 4.84 M 2.35 M 4.49 M 3.84 M 2.7 M

General and Administrative Expenses

- 2.63 M 2.77 M 2.53 M 2.77 M 2.53 M - 2.49 M 2.14 M 2.51 M - 2.51 M 2.35 M 2.44 M - 310 2.9 M 2.74 M 5.64 M 4.55 M 4.29 M 5.09 M 9.38 M 6.56 M 5.1 M 2.8 M 5.1 M 2.8 M 1.75 M 1.81 M 1.75 M 1.81 M 2.12 M 2.21 M - 2.67 M 2.92 M 2.76 M 2.92 M 2.76 M 1.45 M 1.56 M 1.45 M 1.56 M 1.55 M 1.49 M 1.55 M 1.49 M 1.51 M 1.68 M 1.51 M 1.68 M 1.98 M 1.83 M 1.98 M 1.83 M 1.42 M 1.68 M 1.42 K 1.68 M 1.28 K 1.64 M 1.28 M 1.64 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Pluristem Therapeutics PSTI
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Pluristem Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Plus Therapeutics Plus Therapeutics
PSTV
- - $ 301 M usaUSA
Qualigen Therapeutics Qualigen Therapeutics
QLGN
- 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
- - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
- -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
- - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
- - $ 2.64 M usaUSA
Sensei Biotherapeutics Sensei Biotherapeutics
SNSE
- - $ 17.5 M usaUSA
Sonnet BioTherapeutics Holdings Sonnet BioTherapeutics Holdings
SONN
- - $ 826 K usaUSA
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Synlogic Synlogic
SYBX
- - $ 7.07 M usaUSA
Virios Therapeutics, LLC Virios Therapeutics, LLC
VIRI
- 2710.01 % $ 72.9 M usaUSA
Vallon Pharmaceuticals Vallon Pharmaceuticals
VLON
- -6.47 % $ 5.76 M usaUSA
Vaxart Vaxart
VXRT
- -25.06 % $ 46.3 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
- - $ 485 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 33.25 0.78 % $ 1.93 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 13.0 0.08 % $ 5.39 B irlandaIrlanda
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 11.0 0.49 % $ 885 M usaUSA
Passage Bio Passage Bio
PASG
$ 4.5 4.39 % $ 14.4 M usaUSA
AbbVie AbbVie
ABBV
$ 261.59 0.14 % $ 463 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 14.59 0.4 % $ 4.36 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.25 1.74 % $ 278 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.78 1.92 % $ 916 M canadaCanada
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 20.15 0.52 % $ 3.39 B usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 8.09 5.2 % $ 353 M usaUSA
AC Immune SA AC Immune SA
ACIU
$ 2.62 0.77 % $ 264 M schweizSchweiz
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.26 0.85 % $ 645 M usaUSA
Adagene Adagene
ADAG
$ 3.2 0.28 % $ 189 M chinaChina
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.22 0.41 % $ 155 M schweizSchweiz
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 4.01 0.48 % $ 2.68 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 10.03 0.7 % $ 2.39 B usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 28.9 0.45 % $ 4.38 B usaUSA
Agenus Agenus
AGEN
$ 9.93 0.4 % $ 295 M usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.18 1.51 % $ 291 K usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.92 3.83 % $ 237 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 9.3 3.4 % $ 626 B britainBritain
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 1.23 13.79 % $ 73.9 M usaUSA
Alector Alector
ALEC
$ 1.85 0.27 % $ 191 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 5.63 0.18 % $ 55.7 M usaUSA
Alkermes plc Alkermes plc
ALKS
$ 40.52 1.62 % $ 6.67 B irlandaIrlanda
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 1.6 0.57 % $ 353 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 246.74 2.55 % $ 32.3 B usaUSA
Altimmune Altimmune
ALT
$ 2.86 0.34 % $ 252 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.39 2.96 % $ 74.6 M usaUSA
Amgen Amgen
AMGN
$ 421.51 0.07 % $ 227 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.81 0.09 % $ 1.21 B usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 20.14 0.22 % $ 6.31 B usaUSA